Remember Me
Forgot Password

Benefits of Membership
Search By Keyword Or Search By
Diagnosis and Staging of Multiple Myeloma (MM) and Front-Line Therapy for the Transplant-Ineligible Patient: Treatment Planning

Module 1: Diagnosis and Staging of Multiple Myeloma (MM) and Front-Line Therapy for the Transplant-Ineligible Patient: Treatment Planning

Release Date: May 29, 2008
Expiration Date: May 28, 2009
Myeloma Toolkit

Target Audience
This activity has been designed to meet the educational needs of hematologists, oncologists, oncology nurses, oncology pharmacists, and specialty pharmacists who are involved in the care of patients with multiple myeloma.

Statement of Need
Multiple myeloma (MM) is the second most common blood cancer. This hematologic malignancy remains a challenge, with the highest death-to-new-case ratio in oncology. Although myeloma is still considered incurable, survival rates have improved, and clinicians can now employ strategies that promote long-term survival. The reasons for improved survival include enhanced understanding of the pathophysiology of the disease (including the interaction of tumor cells with the bone marrow microenvironment); improved patient risk-stratification based on characteristics such as cytogenetics; better supportive care; refinements in stem-cell transplantation techniques (including tandem transplantation); and the relatively recent introduction of several efficacious therapeutic options, including bortezomib, lenalidomide, and thalidomide.

Educational Objectives
This activity is designed to enhance the participant’s knowledge of myeloma management strategies.

Upon completion of this activity, participants should be better able to:

  • Apply important criteria for evaluating the new MM patient for the purposes of initial and ongoing treatment planning in the community setting
  • Evaluate overall safety and efficacy of available front-line MM regimens for patients who are ineligible for transplant
  • Develop follow-up strategies for patients receiving up-front medical therapy for MM
  • Design mechanisms to improve communication among the interdisciplinary MM care team to improve outcomes for patients with newly diagnosed MM

Performance Goals
This activity is also designed to enhance the participant’s ability to implement appropriate practices based on best evidence.

Upon completion of this activity, participants should be better able to:

  • Enroll patients into appropriate clinical trials

Faculty Information and Disclosures
Sagar Lonial, MD Photo

Sagar Lonial, MD (Chair) click here for bio
Associate Professor of Hematology and Oncology
Director, Translational Research B-cell Malignancy Program
The Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Dr. Lonial has disclosed that he is a consultant for Millennium Pharmaceuticals and Celgene Corporation.

Neal Christiansen, MD Photo

Neal Christiansen, MD click here for bio
Medical Oncologist
South Carolina Oncology Associates
Columbia, South Carolina

Dr. Christiansen has disclosed that he is a consultant for Millennium Pharmaceuticals, Bayer, Genentech, and Sanofi-Aventis. He also serves on speakers bureaus for Genentech and Genomic Health.

William Bensinger, MD Photo

William Bensinger, MD click here for bio
Director of the Autologous Stem Cell Transplant Program
Fred Hutchinson Cancer Center
Professor of Medicine
University of Washington
Seattle, Washington

Dr. Bensinger has disclosed that he serves as a consultant for Millennium Pharmaceuticals. He has received grant/research support from Celgene, Novartis, Biopharma, Amgen, MedImmune, and PDL. He also serves on speakers’ bureaus for Celgene and Millennium.

The planners and managers have no financial or other relationship to products or devices with commercial interests related to the content of this CME activity:

Lisa Tushla, PhD has no real or apparent conflicts of interest.

CEC partners and staff have no real or apparent conflicts of interest.

To receive a statement of credit, you must:

  • Review the full content of the activity and reflect upon its teachings
  • Complete the questions within the activity
  • Complete the evaluation at the end of the activity
Your statement of credit will be issued immediately upon successful completion of the evaluation form.

CEC Logo This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Creative Educational Concepts, Inc. (CEC) and Quest MedEd, LLC. CEC is accredited by the ACCME to provide continuing medical education for physicians.

CEC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ACPE Logo   Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE # 245-999-08-016-H01-P will award 1.0 contact hours (.10 CEUs) of continuing pharmacy education credit. CEC complies with the Criteria for Quality for continuing education programming. Statements of credit will be issued automatically on line.

Eastern Kentucky University, the Division of Continuing Education and Development, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Eastern Kentucky University Logo   Eastern Kentucky University, the Division of Continuing Education and Development, designates this educational activity for 1.0 contact hour. This activity will provide 1.0 contact hour of nursing credit. Licensees are required to retain certificates of completion for a period of five (5) years following the end of their licensure period and submit certificate to the Board of Nursing only upon request.

This activity is complimentary.

Disclosure Declaration
It is the policy of CEC and Quest MedEd, LLC to ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities.

Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Fair balance is achieved through ongoing and thorough review of all presentation materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CEC or Quest MedEd, LLC of any product or manufacturer identified.

Unlabeled Use Disclosure
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.

Supporting Organization
This activity is supported by an educational grant from Millennium Pharmaceuticals, Inc.

Software Requirements

Windows 2000 or above
Internet Explorer 5.5 or Firefox
*Adobe Acrobat Reader
Flash Player Plugin(v7.0.1.9 or greater)

*Required to view Printable PDF Version

Mac OS 10.2.8
*Adobe Acrobat Reader
Flash Player Plugin(v7.0.1.9 or greater)
Internet Explorer is not supported on the Macintosh

Select a Profession to Continue: